Logo

BioSymetrics Signs an Agreement with Janssen and Sema4 to Utilize AI for the Prediction of COVID-19

Share this
BioSymetrics Signs an Agreement with Janssen and Sema4 to Utilize AI for the Prediction of COVID-19

BioSymetrics Signs an Agreement with Janssen and Sema4 to Utilize AI for the Prediction of COVID-19

Shots:

  • The companies will use BioSymetrics Contingent-AI engine to characterize high-risk populations- measure and predict disease progression based on biological risk factors and treatment course and identify markers for clinical phenotype and severity of the disease
  • The focus of the collaboration to predict the onset and severity of COVID-19 among different populations using machine learning
  • The collaboration will operate across several projects with a goal of enabling a vaccine and course of treatment against COVID-19

­ Ref: PRNewswire | Image: Northeast Now

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions